March round-up of pharmaceutical & biotech M&A activity

4 April 2018

The first quarter of 2018 ends quietly, despite the flurry of activity that kicked the year off. That is, with the notable exception of the Cigna-Express deal that was announced this month.

This enormous deal, worth around $67 billion, brings together insurance titans Cigna (NYSE: CI) and the USA's premiere pharmacy chain Express Scripts (NASDAQ: ESRX), wiping the latter's debt and setting up the former as a force to be reckoned with in the all-in-one insurance space.

We've also seen diverging attitudes toward partnership this month. Eisai (TYO: 4523) and Nichi-Iko (TYO: 4541) have aligned to support one another in the competitive generics market, while GSK (LSE: GSK) has spent $13 billion to sever Novartis (VTX: NOVN) from their joint venture with the firm.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK